RARE DISEASE
Juvenile idiopathic arthritis
Juvenile idiopathic arthritis
Juvenile idiopathic arthritis
Synonyms: Juvenile chronic arthritis, Juvenile rheumatoid arthritis
Synonyms: Juvenile chronic arthritis, Juvenile rheumatoid arthritis
Synonyms: Juvenile chronic arthritis, Juvenile rheumatoid arthritis
Drug discovery
21
drugs
With orphan designations
Overview
Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease characterized by persistent joint inflammation (≥6 weeks) in children <16 years, with subtypes classified by clinical features. Diagnosis requires exclusion of alternative causes and may involve elevated inflammatory markers (ESR/CRP) or imaging. Early aggressive therapy with DMARDs/biologics improves remission rates, while untreated cases risk joint damage, growth impairment, and uveitis (15-30% risk) [1][6][11][17]. Management requires multidisciplinary care to address physical, ocular, and psychosocial impacts [1][16].
Population
Burden
25% of adults with JIA require biologics; 44% use glucocorticoids long-term [10][14]
Systemic JIA caregivers lose 25 workdays/year; patients miss 12% of school yearly [4][9]
31% with JIA have concurrent anxiety/depression; 19-20% higher risk of sustained high disease activity with comorbid joint hypermobility [12][15]
Therapies
First-line: Methotrexate ± intra-articular steroids (65% remission in oligoarticular JIA) [8][18]
Biologic escalation: Anti-IL1 (anakinra) or anti-IL6 (tocilizumab) for systemic JIA; TNF inhibitors for polyarticular forms [3][6][13]
Treat-to-target protocols achieve clinical inactivity in 66% within 12 months when initiated early [3][18]
Categories: rare respiratory diseases, rare systemic and rheumatological diseases, rare systemic or rheumatologic diseases of childhood, rare transplant-related disorders
Research Papers
2,863 drug discovery papers about Juvenile idiopathic arthritis, with 4 first-in-class and 16 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2,863 drug discovery papers about Juvenile idiopathic arthritis, with 4 first-in-class and 16 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-12 | Case Report: Telitacicept in the treatment of refractory juvenile idiopathic arthritis: clinical experience from three cases.
Refractory juvenile idiopathic arthritis (JIA) remains difficult to manage, particularly in patients with persistent disease activity despite multiple conventional synthetic disease-modifying antirheumatic drugs and biologic agents. Telitacicept is a dual inhibitor of B-cell activating factor and a proliferation-inducing ligand, but its use in JIA has not been well described. We report three pediatric patients with refractory JIA treated with telitacicept. Case 1 was a 6-year-old girl with extended oligoarticular JIA who presented with recurrent swelling, pain, and limited motion of multiple joints, and elevated inflammatory markers after previous treatment with methotrexate, leflunomide, adalimumab, and intra-articular glucocorticoids. After switching to telitacicept combined with tofacitinib and methotrexate, joint symptoms and inflammatory markers improved, and an ACR70 response was achieved; clinical improvement was maintained during 12 months of follow-up. Case 2 was a 17-year-old boy with RF-positive polyarticular JIA and long-standing active disease involving the wrists and small joints of the hands. After telitacicept was added to background therapy, joint swelling resolved, inflammatory markers normalized, and ACR90 response was achieved during 9 months of follow-up. Case 3 was an 11-year-old boy with systemic JIA whose systemic manifestations had been controlled but who continued to have predominant polyarticular involvement. After telitacicept initiation, wrist swelling and inflammatory markers improved during the first 2 months, and an early ACR90 response was observed; however, relapse occurred at month 3 with recurrence of systemic symptoms, leading to discontinuation of telitacicept. No serious adverse events were observed. One patient developed a mild upper respiratory tract infection that resolved with symptomatic treatment. These cases provide preliminary clinical observations on telitacicept use in refractory JIA. BAFF/APRIL inhibition may warrant further investigation in selected patients with refractory JIA, particularly those with persistent articular involvement; however, prospective controlled studies are needed to evaluate efficacy and safety.
2026-08-11 | Shared genetic architecture and therapeutic targets across paediatric immune-mediated diseases.
Paediatric-onset immune-mediated inflammatory diseases (IMIDs), including juvenile idiopathic arthritis and related rheumatic diseases, remain genetically undercharacterised. We aimed to define shared and category-specific genetic architecture across paediatric IMIDs, compare signals with adult IMIDs, and identify therapeutic opportunities. We analysed 24 paediatric IMIDs classified as autoimmune, polygenic-autoinflammatory, mixed-pattern, or allergic. Genome-wide association analyses included 18,086 cases and 131,019 controls of European ancestry. We estimated single nucleotide polymorphism (SNP)-based heritability, genetic correlations, and polygenic overlap; performed subset-based meta-analysis; and conducted functional annotation, gene prioritisation, pathway and protein network analyses, adult-IMID comparison, and drug-target prioritisation. SNP-based heritability ranged from 28.9% for allergic IMIDs to 61.9% for autoimmune IMIDs. Genetic correlation and polygenic modelling supported partial sharing across categories with category-specific components. Meta-analysis identified 39 genome-wide significant loci outside the Major Histocompatibility Complex (MHC) region, including 15 previously unreported loci; 19 loci were shared between categories. Gene-prioritisation and protein interaction analyses identified a core MHC-centred antigen-presentation network, with category-enriched modules involving complement, innate/barrier pathways, epithelial biology, and type 2 immunity. Enriched pathways included nuclear factor κB signalling, T helper 17 related pathways, Janus kinase-signal transducer and activator of transcription signalling, programmed cell death protein 1/programmed death‑ligand 1, cytotoxic T‑lymphocyte associated protein 4 regulation, and osteoclast differentiation, several of which are relevant to rheumatic diseases. Paediatric IMIDs shared broad polygenic architecture with adult IMIDs, whereas top-ranked genes converged strongly with adult rheumatic diseases. Priority Index analysis identified 178 high-scoring genes, including 43 approved or investigational IMID drug targets. Paediatric-onset IMIDs share core pathways with adult forms but exhibit distinct genetic architecture shaped by age-specific immune and neurodevelopmental biology. These findings provide a genomic framework for paediatric precision medicine, guiding classification, risk prediction, and therapeutic development.
2026-08-11 | The Asia-Pacific League of Associations for Rheumatology Consensus Recommendations on the Management of Systemic Juvenile Idiopathic Arthritis (Juvenile Still's Disease).
The unique characteristics of the Asia Pacific called for the development of pragmatic and viable guidelines for the management of juvenile idiopathic arthritis (JIA). These consensus recommendations represent the second part of the guideline intending to offer an updated and regionally relevant framework for the management of systemic JIA (sJIA)/juvenile Still's disease. A multidisciplinary task force of 35 members from 14 countries, including pediatric and adult rheumatologists as well as patient representatives, was convened. The guideline development followed the GRADE, ADAPTE, and AGREE II frameworks. Relevant international guidelines were critically appraised, and a systematic literature review was performed to address 10 PICO questions. Draft statements were discussed and voted upon using a modified Delphi process, with consensus defined as ≥ 80% agreement. Four overarching principles and eighteen statements, including five statements addressing macrophage activation syndrome (MAS) were formulated. The recommendations align with international guidelines, advocating early use of IL-1/IL-6 inhibitors, avoidance of glucocorticoid monotherapy in sJIA without MAS, promoting tapering of glucocorticoids once inactive disease is achieved, alongside class switching for biologic refractory cases and a treat-to-target approach akin to EULAR/PReS guideline. Additional features include recommending conventional synthetic DMARD when biologics are unavailable and listing the options, acknowledging regional health system heterogeneity in the Asia Pacific, mentioning tapering strategy, discouraging NSAIDs as initial monotherapy, highlighting non-biologic salvage options, and placing less emphasis on sJIA-associated lung diseases. These recommendations provide direction for practitioners caring for sJIA patients in limited resource areas to avoid treatment delay, hence improve overall outcomes. A shared decision approach and treat-to-targets are emphasized.
2026-08-07 | Reappraisal of the Entity of Pediatric Uveitis: Bilateral Iridocyclitis With Retinal Capillaritis (BIRC) in Juveniles in 18 Additional Cases.
Bilateral iridocyclitis with retinal capillaritis (BIRC) in juveniles is a newly recognized entity of juvenile chronic uveitis with no systemic involvement. In this study, 18 additional consecutive patients with BIRC were reported to show that the entity would be useful in the differential diagnosis. Clinical features were retrospectively reviewed in 18 consecutive patients diagnosed with BIRC in juveniles at Okayama University Hospital, Okayama, Japan, between 1996 and 2025. The 18 patients comprised 6 males and 12 females, with an age at onset ranging from 9 to 16 years (median, 13 years). All patients presented with aqueous cells and mutton-fat keratic precipitates in both eyes, and fluorescein angiography revealed varying degrees of optic disc leakage and retinal capillary leakage in the midperipheral to peripheral fundus of both eyes. None had systemic symptoms, including skin rashes, joint pain, or fever, and no abnormalities were detected on blood examinations, urinalysis, or plain chest x-rays. Oral prednisolone, tapered from 30 mg daily, together with topical 0.1% betamethasone four times daily, was administered to five patients: two with optic disc edema and three with macular edema in both eyes or the unilateral eye. The remaining 13 patients were treated with topical 0.1% betamethasone eye drops alone. In patients who developed elevated intraocular pressure, often due to a steroid response, the instillation of topical 0.1% betamethasone was reduced to twice daily, or intraocular pressure-lowering eye drops were used in combination. In two patients who showed relapse of unilateral macular edema after oral prednisolone was tapered or discontinued, oral colchicine (1 mg daily) was introduced, resulting in the subsidence of macular edema. Bilateral uveitis in all 18 patients subsided within 6 months to a few years until 19 years of age, and all topical medications were discontinued, with relapse occurring in only one patient. BIRC in juveniles should be included in the differential diagnosis for school-age children and young adolescents. BIRC follows a chronic course of a few years and subsides completely with a good prognosis. In cases of macular edema or optic disc edema that affects vision, oral corticosteroid treatment is recommended, whereas patients with no sight-threatening signs can be treated with topical corticosteroid eye drops alone. The entity of BIRC may be distinct from juvenile chronic iridocyclitis in young girls with onset at preschool age, which shares common features with juvenile idiopathic arthritis-associated uveitis.
2026-08-02 | Canakinumab for systemic-onset juvenile idiopathic arthritis/Still's disease-effectiveness and safety data from the BiKeR registry.
In Germany, canakinumab is approved for the treatment of refractory systemic juvenile idiopathic arthritis (sJIA)/Still's disease. This study assesses the experience of sJIA/Still's disease patients treated with canakinumab in clinical practice. Data of 79 sJIA/Still's disease patients extracted from the BiKeR registry included patients' and disease characteristics. Three subgroups with disease durations before canakinumab initiation of ≤3 months, >3 to ≤12 months, and >12 months were compared, and 2 with canakinumab as first- and second- or more-line treatment. Disease duration was ≤3 months before canakinumab initiation for 26 patients, >3 to ≤12 months for 24 patients, and >12 months for 29 patients. Thirty-nine patients received canakinumab as first-line treatment and 40 as second- or more-line treatment. Disease severity as assessed by the systemic Juvenile Arthritis Disease Activity Score-10 (sJADAS10) was highest for patients with a disease duration <3 months before canakinumab initiation. In the total cohort, after 3, 6, 12, 18, and 24 months, 86%, 81%, 81%, 75%, and 87% of patients reached inactive disease, respectively. Numerically, more patients reached the treatment goal of inactive disease when the disease duration was shorter before initiation of canakinumab. Minimal disease activity (sJADAS10 ≤6.0) did not differ among subgroups. Compared with second-line, more patients with first-line treatment reached inactive disease at months 6, 12, and 24 after canakinumab initiation. sJADAS10 at 12 months correlated significantly with disease duration before treatment. Canakinumab treatment led to high improvement rates and achievement of inactive disease state, particularly if they are administered early. Data from clinical practice confirm clinical study data.
2026-08-12 | Case Report: Telitacicept in the treatment of refractory juvenile idiopathic arthritis: clinical experience from three cases.
Refractory juvenile idiopathic arthritis (JIA) remains difficult to manage, particularly in patients with persistent disease activity despite multiple conventional synthetic disease-modifying antirheumatic drugs and biologic agents. Telitacicept is a dual inhibitor of B-cell activating factor and a proliferation-inducing ligand, but its use in JIA has not been well described. We report three pediatric patients with refractory JIA treated with telitacicept. Case 1 was a 6-year-old girl with extended oligoarticular JIA who presented with recurrent swelling, pain, and limited motion of multiple joints, and elevated inflammatory markers after previous treatment with methotrexate, leflunomide, adalimumab, and intra-articular glucocorticoids. After switching to telitacicept combined with tofacitinib and methotrexate, joint symptoms and inflammatory markers improved, and an ACR70 response was achieved; clinical improvement was maintained during 12 months of follow-up. Case 2 was a 17-year-old boy with RF-positive polyarticular JIA and long-standing active disease involving the wrists and small joints of the hands. After telitacicept was added to background therapy, joint swelling resolved, inflammatory markers normalized, and ACR90 response was achieved during 9 months of follow-up. Case 3 was an 11-year-old boy with systemic JIA whose systemic manifestations had been controlled but who continued to have predominant polyarticular involvement. After telitacicept initiation, wrist swelling and inflammatory markers improved during the first 2 months, and an early ACR90 response was observed; however, relapse occurred at month 3 with recurrence of systemic symptoms, leading to discontinuation of telitacicept. No serious adverse events were observed. One patient developed a mild upper respiratory tract infection that resolved with symptomatic treatment. These cases provide preliminary clinical observations on telitacicept use in refractory JIA. BAFF/APRIL inhibition may warrant further investigation in selected patients with refractory JIA, particularly those with persistent articular involvement; however, prospective controlled studies are needed to evaluate efficacy and safety.
2026-08-11 | Shared genetic architecture and therapeutic targets across paediatric immune-mediated diseases.
Paediatric-onset immune-mediated inflammatory diseases (IMIDs), including juvenile idiopathic arthritis and related rheumatic diseases, remain genetically undercharacterised. We aimed to define shared and category-specific genetic architecture across paediatric IMIDs, compare signals with adult IMIDs, and identify therapeutic opportunities. We analysed 24 paediatric IMIDs classified as autoimmune, polygenic-autoinflammatory, mixed-pattern, or allergic. Genome-wide association analyses included 18,086 cases and 131,019 controls of European ancestry. We estimated single nucleotide polymorphism (SNP)-based heritability, genetic correlations, and polygenic overlap; performed subset-based meta-analysis; and conducted functional annotation, gene prioritisation, pathway and protein network analyses, adult-IMID comparison, and drug-target prioritisation. SNP-based heritability ranged from 28.9% for allergic IMIDs to 61.9% for autoimmune IMIDs. Genetic correlation and polygenic modelling supported partial sharing across categories with category-specific components. Meta-analysis identified 39 genome-wide significant loci outside the Major Histocompatibility Complex (MHC) region, including 15 previously unreported loci; 19 loci were shared between categories. Gene-prioritisation and protein interaction analyses identified a core MHC-centred antigen-presentation network, with category-enriched modules involving complement, innate/barrier pathways, epithelial biology, and type 2 immunity. Enriched pathways included nuclear factor κB signalling, T helper 17 related pathways, Janus kinase-signal transducer and activator of transcription signalling, programmed cell death protein 1/programmed death‑ligand 1, cytotoxic T‑lymphocyte associated protein 4 regulation, and osteoclast differentiation, several of which are relevant to rheumatic diseases. Paediatric IMIDs shared broad polygenic architecture with adult IMIDs, whereas top-ranked genes converged strongly with adult rheumatic diseases. Priority Index analysis identified 178 high-scoring genes, including 43 approved or investigational IMID drug targets. Paediatric-onset IMIDs share core pathways with adult forms but exhibit distinct genetic architecture shaped by age-specific immune and neurodevelopmental biology. These findings provide a genomic framework for paediatric precision medicine, guiding classification, risk prediction, and therapeutic development.
2026-08-11 | The Asia-Pacific League of Associations for Rheumatology Consensus Recommendations on the Management of Systemic Juvenile Idiopathic Arthritis (Juvenile Still's Disease).
The unique characteristics of the Asia Pacific called for the development of pragmatic and viable guidelines for the management of juvenile idiopathic arthritis (JIA). These consensus recommendations represent the second part of the guideline intending to offer an updated and regionally relevant framework for the management of systemic JIA (sJIA)/juvenile Still's disease. A multidisciplinary task force of 35 members from 14 countries, including pediatric and adult rheumatologists as well as patient representatives, was convened. The guideline development followed the GRADE, ADAPTE, and AGREE II frameworks. Relevant international guidelines were critically appraised, and a systematic literature review was performed to address 10 PICO questions. Draft statements were discussed and voted upon using a modified Delphi process, with consensus defined as ≥ 80% agreement. Four overarching principles and eighteen statements, including five statements addressing macrophage activation syndrome (MAS) were formulated. The recommendations align with international guidelines, advocating early use of IL-1/IL-6 inhibitors, avoidance of glucocorticoid monotherapy in sJIA without MAS, promoting tapering of glucocorticoids once inactive disease is achieved, alongside class switching for biologic refractory cases and a treat-to-target approach akin to EULAR/PReS guideline. Additional features include recommending conventional synthetic DMARD when biologics are unavailable and listing the options, acknowledging regional health system heterogeneity in the Asia Pacific, mentioning tapering strategy, discouraging NSAIDs as initial monotherapy, highlighting non-biologic salvage options, and placing less emphasis on sJIA-associated lung diseases. These recommendations provide direction for practitioners caring for sJIA patients in limited resource areas to avoid treatment delay, hence improve overall outcomes. A shared decision approach and treat-to-targets are emphasized.
2026-08-07 | Reappraisal of the Entity of Pediatric Uveitis: Bilateral Iridocyclitis With Retinal Capillaritis (BIRC) in Juveniles in 18 Additional Cases.
Bilateral iridocyclitis with retinal capillaritis (BIRC) in juveniles is a newly recognized entity of juvenile chronic uveitis with no systemic involvement. In this study, 18 additional consecutive patients with BIRC were reported to show that the entity would be useful in the differential diagnosis. Clinical features were retrospectively reviewed in 18 consecutive patients diagnosed with BIRC in juveniles at Okayama University Hospital, Okayama, Japan, between 1996 and 2025. The 18 patients comprised 6 males and 12 females, with an age at onset ranging from 9 to 16 years (median, 13 years). All patients presented with aqueous cells and mutton-fat keratic precipitates in both eyes, and fluorescein angiography revealed varying degrees of optic disc leakage and retinal capillary leakage in the midperipheral to peripheral fundus of both eyes. None had systemic symptoms, including skin rashes, joint pain, or fever, and no abnormalities were detected on blood examinations, urinalysis, or plain chest x-rays. Oral prednisolone, tapered from 30 mg daily, together with topical 0.1% betamethasone four times daily, was administered to five patients: two with optic disc edema and three with macular edema in both eyes or the unilateral eye. The remaining 13 patients were treated with topical 0.1% betamethasone eye drops alone. In patients who developed elevated intraocular pressure, often due to a steroid response, the instillation of topical 0.1% betamethasone was reduced to twice daily, or intraocular pressure-lowering eye drops were used in combination. In two patients who showed relapse of unilateral macular edema after oral prednisolone was tapered or discontinued, oral colchicine (1 mg daily) was introduced, resulting in the subsidence of macular edema. Bilateral uveitis in all 18 patients subsided within 6 months to a few years until 19 years of age, and all topical medications were discontinued, with relapse occurring in only one patient. BIRC in juveniles should be included in the differential diagnosis for school-age children and young adolescents. BIRC follows a chronic course of a few years and subsides completely with a good prognosis. In cases of macular edema or optic disc edema that affects vision, oral corticosteroid treatment is recommended, whereas patients with no sight-threatening signs can be treated with topical corticosteroid eye drops alone. The entity of BIRC may be distinct from juvenile chronic iridocyclitis in young girls with onset at preschool age, which shares common features with juvenile idiopathic arthritis-associated uveitis.
2026-08-02 | Canakinumab for systemic-onset juvenile idiopathic arthritis/Still's disease-effectiveness and safety data from the BiKeR registry.
In Germany, canakinumab is approved for the treatment of refractory systemic juvenile idiopathic arthritis (sJIA)/Still's disease. This study assesses the experience of sJIA/Still's disease patients treated with canakinumab in clinical practice. Data of 79 sJIA/Still's disease patients extracted from the BiKeR registry included patients' and disease characteristics. Three subgroups with disease durations before canakinumab initiation of ≤3 months, >3 to ≤12 months, and >12 months were compared, and 2 with canakinumab as first- and second- or more-line treatment. Disease duration was ≤3 months before canakinumab initiation for 26 patients, >3 to ≤12 months for 24 patients, and >12 months for 29 patients. Thirty-nine patients received canakinumab as first-line treatment and 40 as second- or more-line treatment. Disease severity as assessed by the systemic Juvenile Arthritis Disease Activity Score-10 (sJADAS10) was highest for patients with a disease duration <3 months before canakinumab initiation. In the total cohort, after 3, 6, 12, 18, and 24 months, 86%, 81%, 81%, 75%, and 87% of patients reached inactive disease, respectively. Numerically, more patients reached the treatment goal of inactive disease when the disease duration was shorter before initiation of canakinumab. Minimal disease activity (sJADAS10 ≤6.0) did not differ among subgroups. Compared with second-line, more patients with first-line treatment reached inactive disease at months 6, 12, and 24 after canakinumab initiation. sJADAS10 at 12 months correlated significantly with disease duration before treatment. Canakinumab treatment led to high improvement rates and achievement of inactive disease state, particularly if they are administered early. Data from clinical practice confirm clinical study data.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
21 orphan drug designations for Juvenile idiopathic arthritis, including 5 approved therapies.
21 orphan drug designations for Juvenile idiopathic arthritis, including 5 approved therapies.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
sirukumab | antibodies | FDA | 2017-07-03 | — | Janssen Research & Development, LLC |
protoplasmic protein matrix, omega-3 fatty oils, vitamins, minerals and trace elements, cell membrane matrix phospholipid, entracellular matrix, lipids, medium chain triglycerides, longer chain triglycerides, carbohydrates, probiotic, and phytonutrients | other | FDA | 2017-01-11 | — | Leonard S. Girsh, MD |
Celecoxib oral liquid suspension | small molecules | FDA | 2017-01-05 | — | NuBioPharma, LLC |
deflazacort | small molecules | FDA | 2015-10-22 | — | PTC Therapeutics, Inc. |
upadacitinib [Rinvoq] | small molecules | FDA | 2015-09-18 | 2024-04-26 | AbbVie, Inc. |
Kre-Celazine | small molecules | FDA | 2013-04-01 | — | All American Pharmaceutical & Natural Foods Corpor |
Givinostat | small molecules | EMA | 2010-01-28 | — | Italfarmaco S.p.A. |
canakinumab [ILARIS] | antibodies | FDA | 2008-09-30 | 2013-05-09 | Novartis Pharmaceuticals Corporation |
nabumetone | small molecules | FDA | 2008-05-05 | — | Cook Pharma |
adalimumab [Humira] | antibodies | FDA | 2005-03-21 | 2008-02-21 | AbbVie Inc. |
rofecoxib | small molecules | FDA | 2004-03-16 | — | MERCK & Co., Inc. |
meloxicam [Mobic] | small molecules | FDA | 2002-11-22 | 2005-08-11 | Avondale Pharmaceuticals |
infliximab | antibodies | FDA | 2002-10-23 | — | Centocor, Inc. |
human gammaglobulin | antibodies | FDA | 2001-05-25 | — | Latona Life Sciences, Inc. |
etanercept [Enbrel] | proteins | FDA | 1998-10-27 | 1999-05-27 | Immunex Corporation |
interferon Beta-1a | proteins | FDA | 1998-10-14 | — | Biogen, Inc. |
Purified type II collagen | proteins | FDA | 1995-02-09 | — | AutoImmune, Inc. |
Gammalinolenic acid | small molecules | FDA | 1994-07-27 | — | Zurier, Robert B. M.D. |
methotrexate | small molecules | FDA | 1993-08-23 | — | Wyeth-Ayerst Laboratories |
Immune globulin intravenous (human) | antibodies | FDA | 1992-12-16 | — | Immuno Clinical Research Corp. |
Interleukin-1 receptor antagonist, human recombinant | proteins | FDA | 1991-09-23 | — | Swedish Orphan Biovitrum AB (publ) (SOBI) |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.